Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617679 · ClinicalTrials.gov registry record · Phase 2
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
A Phase 2 study of Metastatic Endometrial Cancer, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
- 1
- Study location
NCT03617679 is a Phase 2 study of Metastatic Endometrial Cancer that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 79 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03617679, a Phase 2 study of Metastatic Endometrial Cancer, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Rucaparib
Study Locations (1)
Colorado
- University of Colorado Hospital - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03617679
The ClinicalTrials.gov registry entry for NCT03617679 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03617679 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03617679 about?
NCT03617679 is a clinical study titled "Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer". This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
What is the current status of trial NCT03617679?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2019-03-06. Estimated completion is 2026-12.
What conditions does trial NCT03617679 study?
This clinical trial studies the following conditions: Metastatic Endometrial Cancer.
What interventions are being tested in trial NCT03617679?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Rucaparib (DRUG).
Who is sponsoring clinical trial NCT03617679?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03617679 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 2
-
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.